Metastatic malignant neoplasm in the lymph nodes
diseaseOn this page
Also known as Metastases to lymph nodesmetastasis to lymph nodemetastatic malignant neoplasm to the lymph nodesmetastatic neoplasm to the lymph nodemetastatic tumor to lymph nodemetastatic tumour to lymph node
Summary
Metastatic malignant neoplasm in the lymph nodes (MONDO:0005438) is a cancer and 6 clinical trials. Top therapeutic interventions include cabozantinib, ipilimumab, and nivolumab. A subtype of lymph node cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 6
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | metastatic malignant neoplasm in the lymph nodes |
| Mondo ID | MONDO:0005438 |
| EFO | EFO:0004906 |
| NCIT | C4904 |
| UMLS | C0686619 |
| MedGen | 151947 |
| GARD | 0024186 |
| Is cancer (heuristic) | yes |
Also known as: Metastases to lymph nodes · metastasis to lymph node · metastatic malignant neoplasm to the lymph nodes · metastatic neoplasm to the lymph node · metastatic tumor to lymph node · metastatic tumour to lymph node
Disease family
This is a subtype of lymph node cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › immune system cancer › lymphatic system cancer › lymph node cancer › metastatic malignant neoplasm in the lymph nodes
Related subtypes (4): lymph node adenoid cystic carcinoma, intrapelvic lymph node leukemic reticuloendotheliosis, intra-abdominal lymph node mast cell malignancy, lymph node carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 6.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 3 |
| PHASE2/PHASE3 | 1 |
| PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03793166 | PHASE3 | ACTIVE_NOT_RECRUITING | Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study |
| NCT02364557 | PHASE2/PHASE3 | COMPLETED | Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival |
| NCT03796767 | PHASE2 | ACTIVE_NOT_RECRUITING | Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer |
| NCT04071236 | PHASE1/PHASE2 | RECRUITING | Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy |
| NCT05075980 | PHASE2 | ACTIVE_NOT_RECRUITING | Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study |
| NCT03360461 | PHASE2 | COMPLETED | EMI-137 in Laparoscopic Colonic Resections |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CABOZANTINIB | 4 | 1 |
| IPILIMUMAB | 4 | 1 |
| NIVOLUMAB | 4 | 1 |
| RADIUM RA 223 DICHLORIDE | 4 | 1 |
| EMI-137 | 2 | 1 |
| NEDISERTIB | 1 | 1 |
| CHEMBL4215501 | 0 | 1 |
| CHEMBL4849721 | 0 | 1 |
| EXELIXIS | 0 | 1 |